Cellectar Biosciences, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cellectar Biosciences, Inc. (CLRB) on February 25, 2022, reporting events that occurred on February 22, 2022. The filing addresses significant changes in the company's executive leadership, specifically the departure of the Chief Financial Officer and the appointment of a new CFO and Chief Operating Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on personnel changes and executive compensation arrangements.
Material Changes
- Departure of CFO: Dov Elefant resigned as Chief Financial Officer effective February 22, 2022.
- Appointment of CFO: Chad Kolean rejoined the company as Chief Financial Officer on February 22, 2022. He previously served as CFO from 2014 to 2017.
- Promotion to COO: Jarrod Longcor was promoted to Chief Operating Officer on February 22, 2022, having previously served as Chief Business Officer and Senior Vice President of Operations since 2017.
Management Commentary, Risks, and Compensation
Mr. Kolean's employment agreement includes the following terms:
- Base Salary: $340,000 annually.
- Performance Bonus: Target amount equal to 40% of base salary.
- Severance: Nine months of severance for dismissal without cause or resignation for good reason; eighteen months if such events occur within twelve months following a change in control.
- Equity Grant: Option to purchase 150,000 shares of common stock at the closing price on February 22, 2022. The option vests annually over three years (1/3 per anniversary).
The filing states there are no family relationships between Mr. Kolean or Mr. Longcor and any directors or executive officers, and no undisclosed arrangements regarding their selection.
Investor Verification Checklist
- Verify the stock price on February 22, 2022, to determine the exercise price of Mr. Kolean's 150,000 share option grant.
- Review the company's cash position to assess the impact of the new executive compensation package on liquidity.
- Monitor future filings for the transition of financial reporting responsibilities from the former CFO to Mr. Kolean.
- Check for any subsequent press releases or 8-Ks regarding the strategic direction under the new leadership team.